Philip E. V. Van Kerrebroeck

Philip E. V. Van Kerrebroeck

Auto-generated profile, based on publicly available information

Philip E. V. Van Kerrebroeck

Department of Urology, University Hospital Maastricht, Maastricht, The Netherlands

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Journal of Urology
Verified
Journal Article
Closed access
PKPhilip E.V. van Kerrebroeck
Philip E.V. van Kerrebroeck
AVAnco C. van Voskuilen
Anco C. van Voskuilen
John P. F. A. HeesakkersJohn P. F. A. Heesakkers
John P. F. A. Heesakkers
ANAugust A.B. Lycklama Á Nijholt
August A.B. Lycklama Á Nijholt
SSSteven Siegel
Steven Siegel
UHUbi van Den Hombergh
Ubi van Den Hombergh
This 5-year, prospective, multicenter trial evaluated the long-term safety and efficacy of sacral neuromodulation in patients with refractory urge incontinence, urgency frequency and retention. A total of 17 centers worldwide enrolled 163 patients (87% female). Following test stimulation 11 patients declined implantation and 152 underwent implantation using InterStim. Of those treated with implantation 96 (63.2%) had urge incontinence, 25 (16.4%) had urgency frequency and 31 (20.4%) had retention. Voiding diaries were collected annually for 5 years. Clinical success was defined as 50% or greater improvement from baseline in primary voiding diary variable(s). Data for all implanted cases were reported. For patients with urge incontinence mean leaking episodes per day decreased from 9.6 +/- 6.0 to 3.9 +/- 4.0 at 5 years. For patients with urgency frequency mean voids per day decreased from 19.3 +/- 7.0 to 14.8 +/- 7.6, and mean volume voided per void increased from 92.3 +/- 52.8 to 165.2 +/- 147.7 ml. For patients with retention the mean volume per catheterization decreased from 379.9 +/- 183.8 to 109.2 +/- 184.3 ml, and the mean number of catheterizations decreased from 5.3 +/- 2.8 to 1.9 +/- 2.8. All changes were statistically significant (p <0.001). No life threatening or irreversible adverse events occurred. In 102 patients 279 device or therapy related adverse events were observed. At 5 years after implantation 68% of patients with urge incontinence, 56% with urgency frequency and 71% with retention had successful outcomes. This long-term study demonstrates that InterStim therapy is safe and effective for restoring voiding in appropriately selected cases refractory to other forms of treatment.


30 January 2003 in Urological Research
Verified
Journal Article
Closed access
PKPhilip van Kerrebroeck
Philip van Kerrebroeck
FMFlip ter Meulen
Flip ter Meulen
EFElisabeth Farrelly
Elisabeth Farrelly
GLGregor Larsson
Gregor Larsson
LELena Edwall
Lena Edwall
AFAino Fianu-Jonasson
Aino Fianu-Jonasson

23 October 2010 in International Urogynecology Journal
Verified
Journal Article
Open access
PDF file
PKPhilip E. V. Van Kerrebroeck
Philip E. V. Van Kerrebroeck
Sacral neuromodulation has been developed to treat chronic lower urinary tract symptoms, resistant to classical conservative therapy. The suspected mechanisms of action include afferent stimulation of the central nervous system and modulation of activity at the level of the brain. Typical neuromodulation is indicated both in overactivity and in underactivity of the lower urinary tract. In the majority of patients, a unilateral electrode in a sacral foramen and connected to a pulse generator is sufficient to achieve significant clinical results also on long term. In recent years, other urological indications have been explored.

1 January 2001 in European Urology
Verified
Journal Article
Closed access
PDF file
PKPh.E.V. Van Kerrebroeck
Ph.E.V. Van Kerrebroeck
Objectives: To assess the long-term efficacy and safety of alfuzosin 10 mg OD in patients with symptomatic BPH. Methods: Patients (>50 years) were randomised to alfuzosin 10 mg OD, alfuzosin 2.5. mg t.i.d. or placebo for 3 months. Open-label alfuzosin 10 mg OD was continued for up to 1 year. Efficacy assessments included the International Prostate Symptom Score (I-PSS) and quality of life index and uroflowmetry. Results: At 3 months, there was a significant reduction in I-PSS and a significant improvement in peak flow rate for both alfuzosin groups compared with placebo (p < 0.05). Vasodilatory adverse experiences were more common in the alfuzosin 2.5 mg group than the 10 mg OD group. Improvements in symptoms and flow rate with alfuzosin 10 mg OD were maintained for up to 12 months. Conclusion: Alfuzosin 10 mg OD is an effective treatment for symptomatic BPH for at least 12 months, with a better cardiovascular safety profile than the immediate release formulation.

1 March 2003 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
PKPhilip Van Kerrebroeck
Philip Van Kerrebroeck
Overactive bladder is a chronic condition that affects millions of people worldwide. Antimuscarinic agents are the predominant pharmacotherapy for overactive bladder. Tolterodine is a potent, competitive muscarinic receptor antagonist that exhibits in vivo selectivity for the bladder over other tissues that contain muscarinic receptors (such as the salivary glands and the eye), which helps explain why it has such a good tolerability profile compared to oxybutynin. Tolterodine is the first drug specifically developed for the treatment of overactive bladder and is available as both an immediate- and extended-release formulation. This review summarizes the primary antimuscarinic profile of tolterodine and reviews the efficacy, safety and tolerability of tolterodine in studies of patients with overactive bladder.